XBiotech Inc. (XBIT): Price and Financial Metrics
GET POWR RATINGS... FREE!
XBIT POWR Grades
- Value is the dimension where XBIT ranks best; there it ranks ahead of 87.24% of US stocks.
- XBIT's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
- XBIT's current lowest rank is in the Momentum metric (where it is better than 9.5% of US stocks).
XBIT Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for XBIT is 0.07 -- better than just 10.75% of US stocks.
- For XBIT, its debt to operating expenses ratio is greater than that reported by just 0.49% of US equities we're observing.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.02 for XBiotech Inc; that's greater than it is for just 5.75% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to XBiotech Inc are MNOV, ACRS, RESN, IONS, and CCXI.
- Visit XBIT's SEC page to see the company's official filings. To visit the company's web site, go to www.xbiotech.com.
XBIT Valuation Summary
- XBIT's price/sales ratio is 19.3; this is 70.04% higher than that of the median Healthcare stock.
- XBIT's price/sales ratio has moved NA NA over the prior 78 months.
- Over the past 78 months, XBIT's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for XBIT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| XBIT | 2021-08-31 | 19.3 | 1.4 | -40.3 | -9.4 |
| XBIT | 2021-08-30 | 19.5 | 1.4 | -40.9 | -9.8 |
| XBIT | 2021-08-27 | 19.4 | 1.4 | -40.7 | -9.7 |
| XBIT | 2021-08-26 | 19.2 | 1.4 | -40.2 | -9.4 |
| XBIT | 2021-08-25 | 19.1 | 1.4 | -39.9 | -9.2 |
| XBIT | 2021-08-24 | 19.2 | 1.4 | -40.1 | -9.3 |
XBIT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- XBIT has a Quality Grade of D, ranking ahead of 12.65% of graded US stocks.
- XBIT's asset turnover comes in at 0.071 -- ranking 291st of 677 Pharmaceutical Products stocks.
- QLGN, CPHI, and DRNA are the stocks whose asset turnover ratios are most correlated with XBIT.
The table below shows XBIT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.071 | 0.391 | -0.195 |
| 2021-03-31 | 0.102 | 0.248 | -0.138 |
| 2020-12-31 | 0.124 | 0.215 | -0.116 |
| 2020-09-30 | 0.082 | 0.166 | 7.794 |
| 2020-06-30 | 0.070 | 0.188 | 10.040 |
| 2020-03-31 | 0.039 | 0.237 | 14.665 |
XBIT Stock Price Chart Interactive Chart >
XBIT Price/Volume Stats
| Current price | $13.95 | 52-week high | $21.00 |
| Prev. close | $14.89 | 52-week low | $13.85 |
| Day low | $13.85 | Volume | 98,500 |
| Day high | $14.92 | Avg. volume | 85,513 |
| 50-day MA | $15.77 | Dividend yield | N/A |
| 200-day MA | $17.21 | Market Cap | 423.77M |
XBiotech Inc. (XBIT) Company Bio
XBiotech Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various different diseases. The company was founded in 2005 and is based in Austin, Texas.
Latest XBIT News From Around the Web
Below are the latest news stories about XBiotech Inc that investors may wish to consider to help them evaluate XBIT as an investment opportunity.
XBiotech's (NASDAQ:XBIT) investors will be pleased with their fantastic 514% return over the last three yearsWe think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many... |
Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech''s Natrunix Anti-Cancer Therapy in Pancreatic CancerAUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT ) ("XBiotech") today announced that Benjamin Musher M.D., will chair XBiotech''s clinical program for pancreatic cancer. The Company is developing a novel cancer drug, Natrunix, to be used in combination with cytotoxic anti-cancer agents. Natrunix specifically blocks a substance that has been shown to stimulate tumor blood supply and break down connective tissue, which can support tumor growth and destruction of healthy tissue. The anti-inflammatory activity of Natrunix is also being evaluated for its ability to reduce the toxicity and injury caused by the cytotoxic anti-cancer agents themselves. XBiotech''s pancreatic cancer program, 1-BETTER, launched with a randomized, double-blind, placebo-controlled Phase... |
XBiotech Inc.: Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech''s Natrunix Anti-Cancer Therapy in Pancreatic CancerAUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) ("XBiotech") today announced that Benjamin Musher M.D., will chair XBiotech''s clinical program for pancreatic cancer. |
Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotechs Natrunix Anti-Cancer Therapy in Pancreatic CancerAUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (XBiotech) today announced that Benjamin Musher M.D., will chair XBiotechs clinical program for pancreatic cancer. The Company is developing a novel cancer drug, Natrunix, to be used in combination with cytotoxic anti-cancer agents. Natrunix specifically blocks a substance that has been shown to stimulate tumor blood supply and break down connective tissue, which can support tumor growth and destruction of healthy tissue. The anti-inflammatory activity of Natrunix is also being evaluated for its ability to reduce the toxicity and injury caused by the cytotoxic anti-cancer agents themselves. |
Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic CancerAUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced that Benjamin Musher M.D., will chair XBiotech’s clinical program for pancreatic cancer. The Company is developing a novel cancer drug, Natrunix™, to be used in combination with cytotoxic anti-cancer agents. Natrunix™ specifically blocks a substance that has been shown to stimulate tumor blood supply and break down connective tissue, which can support tumor growth and destruction of health |
XBIT Price Returns
| 1-mo | -13.52% |
| 3-mo | -15.76% |
| 6-mo | -18.52% |
| 1-year | -28.06% |
| 3-year | 338.68% |
| 5-year | 7.47% |
| YTD | -10.86% |
| 2020 | -16.15% |
| 2019 | 267.42% |
| 2018 | 28.93% |
| 2017 | -61.07% |
| 2016 | -6.90% |
Loading social stream, please wait...